Education
About Us
Working with TipRanks
Follow Us
Immuron Limited (AU:IMC)
:IMC
IMC Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.11
Previous CloseN/A
Volume128.40K
Average Volume (3M)57.63K
Market Cap
AU$14.97M
Enterprise ValueAU$114.20K
Total Cash (Recent Filing)AU$7.74M
Total Debt (Recent Filing)AU$135.62K
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 29, 2025Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding233,959,010
10 Day Avg. Volume73,289
30 Day Avg. Volume57,627
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)2.46
Price to Sales (P/S)0.00
P/FCF Ratio-10.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Immuron Limited News
PremiumCompany Announcements
BNYMC Increases Stake in Immuron Limited
PremiumCompany Announcements
Immuron Limited Issues New Shares in Compliance with Corporations Act
PremiumCompany Announcements
Immuron Limited Poised for Record Sales and Clinical Advancements
PremiumCompany Announcements
Immuron Limited Issues New Shares in Compliance with Corporations Act
PremiumCompany Announcements
Immuron Limited Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Immuron Limited Announces Proposed Securities Issue
PremiumCompany Announcements
Immuron Limited Announces New Share IssuancePremiumCompany Announcements
Immuron Limited Announces Cessation of Performance RightsOptions Prices
Currently, No data available
---
Ownership Overview
0.26% Insiders
―
Mutual Funds
― Other Institutional Investors
99.74% Public Companies and
Individual Investors
IMC FAQ
What was Immuron Limited’s price range in the past 12 months?
Immuron Limited lowest share price was AU$0.05 and its highest was AU$0.11 in the past 12 months.
What is Immuron Limited’s market cap?
Immuron Limited’s market cap is AU$14.97M.
When is Immuron Limited’s upcoming earnings report date?
Immuron Limited’s upcoming earnings report date is Aug 29, 2025 which is in 53 days.
How were Immuron Limited’s earnings last quarter?
Immuron Limited released its earnings results on Feb 26, 2025. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of AU$0 by -AU$0.011.
Is Immuron Limited overvalued?
According to Wall Street analysts Immuron Limited’s price is currently Overvalued.
Does Immuron Limited pay dividends?
Immuron Limited does not currently pay dividends.
What is Immuron Limited’s EPS estimate?
Immuron Limited’s EPS estimate is 0.
How many shares outstanding does Immuron Limited have?
Immuron Limited has 233,959,010 shares outstanding.
What happened to Immuron Limited’s price movement after its last earnings report?
Immuron Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of AU$0. Following the earnings report the stock price went up 2.564%.
Which hedge fund is a major shareholder of Immuron Limited?
Currently, no hedge funds are holding shares in AU:IMC
Immuron Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IMC Sentiment 70%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.20%
12-Months-Change
Fundamentals
Return on Equity
-52.70%
Trailing 12-Months
Asset Growth
-40.75%
Trailing 12-Months
Company Description
Immuron Limited
Immuron Limited (IMC) is an Australian biopharmaceutical company focused on the development and commercialization of orally-delivered targeted polyclonal antibodies for the treatment of infectious diseases. The company operates primarily in the biotechnology and pharmaceuticals sectors, leveraging its proprietary technology platform to develop products that address significant unmet medical needs. Immuron's core products include Travelan, a preventative treatment for travelers' diarrhea, and other therapeutic candidates aimed at treating a range of infectious and immune-mediated diseases.
Technical Analysis
Noxopharm Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Anatara Lifesciences Ltd
―
Neuroscientific Biopharmaceuticals Ltd.
―